Navigation Links
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema

vailable in the second half of 2007 after the data have been collected, verified and analyzed. In addition to the pivotal CHANGE trial, Lev has initiated two open-label studies to provide HAE patients with continued access to C1-INH.

Lev intends to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, during the second quarter of 2007 for marketing approval of C1-INH for the acute treatment of HAE attacks based on the results of the first portion of the CHANGE study. The results from the prophylactic portion of the study, when available and if supportive, are expected to be used to expand the label indication.

About Hereditary Angioedema

HAE is a genetic disorder characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the abdomen, and the larynx. The inflammation can be disfiguring, debilitating, or, in the case of laryngeal attacks, life-threatening. HAE is caused by a deficiency of the plasma protein C1-INH. While there is no approved therapy for the condition in the U.S., replacement therapy with C1-INH is the treatment of choice for HAE in Europe, where it has been used safely and effectively for over 30 years. There are estimated to be approximately 10,000 people with HAE in the U.S.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Lev's C1-INH has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. The Company has also received fast track designation status from the FDA, which facil
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Philanthropic giving ... awareness of societal issues and needs. Money for Good 2015, released today by Camber ... it. There’s an annual potential to mobilize up to $22B in new philanthropic giving ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State University ... across the country in stemming sexual assaults on their campuses. , The free, ... consortium of sexual assault researchers and student affairs professionals responding to calls by ...
(Date:9/1/2015)... Ill. (PRWEB) , ... September 01, 2015 , ... ... done by members of the American Society for Dermatologic Surgery, according to a ... The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... computing and collaboration, announces Splashtop Business for Remote Support , a solution ... support solution. Unhappy with the escalating renewal prices and inadequate customer services ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in ... and beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
... HPRT1 lead to very specific self-destructive behavior. Boys with ... slam their arms into doorways and otherwise harm themselves. ... gene don,t behave differently than normal mice. Researchers at ... related to HPRT1, present in humans but not in ...
... HealthDay Reporter , WEDNESDAY, July 27 (HealthDay News) -- ... doesn,t improve detection of invasive breast cancer, new research suggests. ... will be called back for further testing, according to the ... National Cancer Institute . ,All in all, we found ...
... News) -- Greater breast density is associated with an ... traits, new research says. In the study, published ... Journal of the National Cancer Institute , researchers used ... with breast cancer and a control group of 1,794 ...
... Using human breast cancer cells and the protein that causes fireflies ... some breast cancer cells become resistant to the anticancer effects of ... "dimmer switches" that apparently control how a breast cancer gene responds ... July 7 by Human Molecular Genetics , the scientists show ...
... 27, 2011) Using computed tomography (CT), researchers have identified ... with chronic obstructive pulmonary disease (COPD) that are associated with ... are published online in the journal Radiology . ... of the lungs, and is a leading cause of death ...
... measurements in humans show that potentially harmful haloacetic acids ... minutes after exposure to chlorinated water where HAAs form ... in the ACS journal Environmental Science & Technology ... the urine of swimming pool workers. Mercedes Gallego ...
Cached Medicine News:Health News:Gene gives clues to self-injurious behavior in rare disorder 2Health News:Computer-Aided Mammography Doesn't Improve Breast Cancer Detection: Study 2Health News:Computer-Aided Mammography Doesn't Improve Breast Cancer Detection: Study 3Health News:Greater Breast Density May Raise Cancer Risk 2Health News:Johns Hopkins researchers discover how some breast cancers alter their sensitivity to estrogen 2Health News:CT shows changes in lungs associated with COPD flare-ups 2
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: